New studies of low-molecular-weight heparin in pregnancy.

Abstract

Several aspects of the diagnostic and therapeutic management of women with venous thrombosis are uncertain, because of the absence of adequately sized observational or intervention studies. Here, I will discuss the rationale and design of two currently ongoing investigator-initiated, international, randomized controlled trials of LMWHin pregnancy. The Highlow study (www.highlowstudy.org; NCT Clinicaltrials.gov) 01828697) investigates two doses of low-molecular-weight heparin to prevent recurrent venous thromboembolism (VTE) in pregnant women with a history of VTE. The ALIFE2 study (www.alife2study.org; www.trialregister.nl, NTR 3361) investigates the effect of LMWH on live birth in women with inherited thrombophilia and two or more miscarriages.

• Authors: Saskia Middeldorp
• Journal: Thrombosis research (Thromb Res) Vol. 135 Suppl 1 Pg. S26-9 (Feb 2015) ISSN: 1879-2472 [Electronic] United States
• PMID: 25903529 (Publication Type: Journal Article, Review)
• Copyright: © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Heparin, Low-Molecular-Weight

Topics

• Abortion, Habitual (chemically induced, prevention & control)
• Female
• Heparin, Low-Molecular-Weight (administration & dosage, adverse effects)
• Humans
• Live Birth
• Pregnancy
• Pregnancy Complications, Cardiovascular (diagnosis, drug therapy)
• Randomized Controlled Trials as Topic
• Treatment Outcome
• Venous Thromboembolism (diagnosis, drug therapy)